Comparative Risk of Incident and Recurrent Acute Anterior Uveitis across Different Biological Agents in Patients with Ankylosing Spondylitis
DOI 10.1093/rheumatology/keae003 Epub ahead of print
Kwon, et al. found that adalimumab exposure significantly reduced risk of incident and recurrent acute anterior uveitis (AAU) versus etanercept exposure and bDMARD non-exposure. Furthermore, exposure to etanercept significantly increased risk of incident and recurrent AAU versus bDMARD non-exposure.
Drug Survival, Effectiveness and Safety of Ixekizumab for Moderate-to-severe Psoriasis up to 5 Years
J Eur Acad Dermatol Venereol 2023 doi 10.1111/jdv.19682 Epub ahead of print
This monocentric, retrospective clinical study by Mastorino, et al. found that ixekizumab demonstrated efficacy an safety in patients with PsA and PsO for up to five years. Being a super-responder was significantly associated with a lower rate of discontinuation, while high BMI was associated with a lower achievement of more than one PSAI measure up to Week 104.
A Randomized, Double-Blind, Placebo-Controlled Phase 2a Study of Tildrakizumab Efficacy and Safety in Patients with Active Ankylosing Spondylitis
J Clin Rheumatol. 2023;29(5):223–229 doi: 10.1097/RHU.0000000000001973
Phase 2a study assessing the efficacy and safety of tildrakizumab in patients with active AS fails to meet the primary endpoint.
Long-Term Safety and Efficacy of Ixekizumab in Patients with Axial Spondyloarthritis: 3-year Data from the COAST Program
J Rheumatol. 2023;50(8):1020–1028 doi: 10.3899/jrheum.221022
Three-year data from the ixekizumab (IXE) COAST programme provide additional evidence that patients with axSpA receiving IXE experience long-term safety, and sustained improvements in efficacy outcomes, at 3 years.
The effect of ixekizumab on axial manifestations in patients with psoriatic arthritis from two phase III clinical trials: SPIRIT-P1 and SPIRIT-P2
Ther Adv Musculoskelet Dis. 2023;15:1759720X231189005 doi: 10.1177/1759720X231189005
Post-hoc analysis of SPIRIT-P1 and SPIRIT-P2 concludes that ixekizumab (IXE) is effective in improving axial symptoms in patients with active PsA presenting with axial manifestations.
A Patient with Adalimumab-induced Refractory Paradoxical Palmoplantar Pustulosis was Successfully Treated by Ixekizumab: A Case Report
Clin Cosmet Investig Dermatol. 2023;16:879–881 doi 10.2147/CCID.S406164
Ixekizumab, has been shown to be efficacious against paradoxical palmoplantar pustulosis which has been reported following the administration of therapeutic TNFi. Following the increased use of biologic therapies that improve patients’ quality of life are causing paradoxical adverse effects
Real-world Treatment Patterns and Use of Adjunctive Pain and Anti-inflammatory Medications Among Patients with Psoriatic Arthritis Treated With IL-17A Inhibitors In The United States
J Manag Care Spec Pharm. 2022 doi: 10.18553/jmcp.2022.22144
In this study ixekizumab and secukinumab patients had similar treatment patterns. It was also surmised that the use of adjunctive pain and anti-inflammatory medications were similar between therapies. In coming to this conclusion investigators aimed to compare treatment patterns and use of pain and anti-inflammatory medications between patients with PsA initiating ixekizumab and secukinumab in two cohorts of patients from…(add here where is the population coming from).
Comparative Performance of Composite Measures From Two Phase III Clinical Trials of Ixekizumab in Psoriatic Arthritis
RMD Open. 2022 doi: 10.1136/rmdopen-2022-002457
In this latest investigation into ixekizumab more patients achieved targets assessed by mCPDAI and DAPSA than with other composites. This study assess’ the concordance and variability in performance of the composite measures in patients with PsA, as well as to provide greater granularity to the frequency and severity of residual symptoms in patients who achieve treatment targets.
Efficacy and Safety of Ixekizumab Versus Adalimumab in Biologic-naïve Patients with Active Psoriatic Arthritis and Moderate-to-severe Psoriasis: 52-week Results from the Randomized SPIRIT-H2H Trial
Dermatol Pract Concept. 2022 doi: 10.5826/dpc.1202a104
Ixekizumab (IXE)-treated patients achieved significantly greater simultaneous PASI100 and ACR50 responses through W52 versus adalimumab (ADA)-treated, confirming IXE as an efficacious and safe treatment. This study investigated the efficacy and safety of IXE and ADA in the subgroup of patients with PsA and moderate-to-severe PsO through W52.
Recapture and Retreatment Rates with Ixekizumab After Withdrawal of Therapy in Patients with Axial Spondyloarthritis: Results at Week 104 From a Randomised Placebo-controlled Withdrawal Study
Ann Rheum Dis. 2022 doi: 10.1136/ard-2022-222731
The present analysis demonstrated that patients continuously treated with IXE were less likely to experience flare compared with patients receiving placebo. The aim of this study was to evaluate the recapture of response with open-label IXE retreatment at week 104 in patients with axSpA who flared after withdrawal of IXE therapy.